XBiotech Inc. (XBIT) Income Statement
XBIT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsXBIT revenue and net income
XBIT profit margins
XBIT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
XBIT quarterly EPS vs estimates
XBiotech beat the analyst EPS estimate in 0 of the last 3 quarters. Next report: November 11, 2026.
XBIT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $300,000 | $4.0M | $18.4M | $44.0M | $12.7M | $0 | $0 | $0 |
| Cost of revenue | $1.7M | $1.7M | $1.7M | $651,000 | $5.8M | $34.5M | $2.4M | $2.4M | $1.5M | $698,000 |
| Gross profit | −$1.7M | −$1.7M | −$1.7M | $3.4M | $12.6M | $9.4M | −$2.4M | −$2.4M | −$1.5M | −$698,000 |
| Research & development | $47.4M | $37.8M | $32.8M | $31.5M | $28.3M | $9.5M | $24.1M | $15.7M | $26.4M | $42.5M |
| Sales, general & admin | $8.3M | $4.7M | $4.7M | $6.3M | $9.4M | $18.2M | $7.1M | $5.3M | $7.6M | $10.3M |
| Total operating expenses | $54.0M | $42.5M | $37.5M | $37.8M | $37.7M | $27.7M | $28.9M | $18.6M | $32.6M | $52.1M |
| Operating income | −$55.7M | −$42.5M | −$37.5M | −$34.5M | −$25.1M | −$18.3M | −$31.2M | −$21.0M | −$34.1M | −$52.8M |
| Interest income | $5.7M | $9.8M | $10.3M | $3.8M | $467,000 | $2.5M | $564,000 | $400,000 | $354,000 | $49,000 |
| Interest expense | $88,000 | $807,000 | $0 | $902,000 | $1.1M | $8.9M | $748.8M | $0 | $0 | $0 |
| Income before taxes | −$45.3M | −$38.6M | −$24.3M | −$33.6M | −$25.5M | −$12.8M | $718.5M | −$21.1M | −$33.1M | −$52.8M |
| Income taxes | $235,000 | −$32,000 | $244,000 | −$688,000 | −$8.0M | −$1.6M | $49.8M | −$144,000 | −$909,000 | −$2,000 |
| Net income | −$45.5M | −$38.5M | −$24.6M | −$32.9M | −$17.4M | −$11.2M | $668.6M | −$21.1M | −$33.1M | −$52.8M |
| EBITDA | −$43.5M | −$36.0M | −$22.6M | −$31.0M | −$22.8M | −$16.0M | $720.8M | −$18.7M | −$32.6M | −$52.1M |
| EPS (diluted) | −$1.50 | −$1.26 | −$0.81 | −$1.09 | −$0.29 | −$0.18 | $14.12 | −$1.13 | −$1.04 | −$1.63 |
| Gross margin | — | — | −581.3% | 83.8% | 68.4% | 21.5% | −18.6% | — | — | — |
| Operating margin | — | — | −12,503.3% | −860.1% | −136.4% | −41.5% | −246.3% | — | — | — |
| Net margin | — | — | −8,185.7% | −820.4% | −94.7% | −25.5% | 5,272.7% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $867,000 | $0 | $0 | $0 | $2.6M | $2.6M | $0 |
| Cost of revenue | — | $332,000 | $378,000 | $427,000 | $439,000 | $442,000 | — | $439,000 | $435,000 | $434,000 | $434,000 | $432,000 |
| Gross profit | — | −$332,000 | −$378,000 | −$427,000 | −$439,000 | −$442,000 | — | −$439,000 | −$435,000 | −$434,000 | −$434,000 | −$432,000 |
| Research & development | $5.3M | $5.2M | $25.4M | $5.1M | $5.3M | $11.6M | $7.8M | $7.1M | $13.0M | $9.8M | $7.8M | $7.5M |
| Sales, general & admin | $850,000 | $1.1M | $4.4M | $967,000 | $1.0M | $1.9M | $927,000 | $777,000 | $2.0M | $1.0M | $783,000 | $973,000 |
| Total operating expenses | $6.1M | $5.9M | $29.8M | $6.0M | $6.3M | $13.6M | $8.7M | $7.9M | $15.0M | $10.9M | $8.2M | $8.5M |
| Operating income | −$6.1M | −$6.3M | −$29.8M | −$6.0M | −$6.3M | −$13.6M | −$8.7M | −$7.9M | −$15.0M | −$10.9M | −$8.6M | −$8.5M |
| Interest income | $885,000 | $914,000 | $1.2M | $1.4M | $1.5M | $1.5M | $2.1M | $2.4M | $2.7M | $2.7M | $2.6M | $2.5M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $88,000 | $204,000 | $203,000 | $200,000 | $3.3M | $3.3M | $0 |
| Income before taxes | −$6.7M | −$5.5M | −$26.8M | −$5.9M | −$1.7M | −$10.9M | −$10.5M | −$5.0M | −$13.0M | −$10.0M | −$4.7M | −$7.1M |
| Income taxes | $46,000 | $49,000 | $76,000 | $102,000 | $28,000 | $29,000 | −$41,000 | $9,000 | −$25,000 | $25,000 | −$99,000 | $308,000 |
| Net income | −$6.7M | −$5.5M | −$26.9M | −$6.0M | −$1.8M | −$10.9M | −$10.5M | −$5.0M | −$13.0M | −$10.0M | −$4.6M | −$7.4M |
| EBITDA | −$4.4M | −$5.1M | −$26.4M | −$5.5M | −$1.3M | −$10.3M | −$9.9M | −$4.4M | −$12.6M | −$9.3M | −$4.3M | −$6.6M |
| EPS (diluted) | −$0.22 | −$0.18 | −$0.88 | −$0.20 | −$0.06 | −$0.36 | −$0.34 | −$0.16 | −$0.43 | −$0.33 | −$0.15 | −$0.24 |
| Gross margin | — | — | — | — | — | −51.0% | — | — | — | −16.6% | −16.6% | — |
| Operating margin | — | — | — | — | — | −1,562.9% | — | — | — | −414.2% | −327.7% | — |
| Net margin | — | — | — | — | — | −1,255.4% | — | — | — | −381.8% | −176.9% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in XBIT's financial statements (latest annual report filed March 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
XBIT financial results
XBiotech reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $45.5 million. Diluted earnings per share came to −$1.50.
See the XBIT stock overview for the latest quote and news, or the XBIT chart for price history and technical indicators.
XBIT income statement FAQ
Does XBiotech have revenue?
XBiotech reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is XBiotech profitable?
No. XBiotech reported a net loss of $45.5 million in fiscal 2025.
How much does XBiotech spend on research and development?
XBiotech spent $47.4 million on research and development in fiscal 2025.
What are XBiotech's earnings per share?
XBiotech earned $-1.50 per diluted share in fiscal 2025, compared with $-1.26 a year earlier.
When will XBiotech report its next earnings?
XBiotech is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does XBiotech's fiscal year end?
XBiotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 13, 2026.